



ISAP 34th Annual Meeting

**2025 Commercial
Support Prospectus**
Friday, October 10, 2025

The Westin Riverwalk
420 West Market Street, San Antonio, Texas, USA

EXCLUSIVE EVENTS



LIFETIME ACHIEVEMENT AWARD

Thomas Schnider, MD

Head of Department Institut für
Anästhesiologie at Kantonsspital
St. Gallen, Switzerland
(retired August 2023)



MOHAMED NAGUIB LECTURE

Guy Weinberg, MD

Professor, Department of Anesthesiology
University of Illinois - College of Medicine
Chicago, Illinois

ISAP Commercial Supporter Information

Mission Statement

- To advance the study of anesthetic pharmacology, to contribute to its growth and influences, to encourage specialization in the field of anesthetic pharmacology and to encourage high ethical and professional standards by fostering and encouraging research, education, and scientific progress in anesthetic pharmacology;
- To publish and encourage the dissemination to the profession and to the public of information concerning the role of anesthetic pharmacology, to issue publications of scientific and cultural interest and to sponsor professional meetings or conferences for these purposes;
- And to support, encourage and participate in the development and promotion of policies and programs of other professional organizations regarding anesthetic pharmacology.

Annual Meeting

- ISAP Annual Meeting if in person is held in conjunction with the American Society of Anesthesiologists (ASA) Annual Meeting. The 2025 meeting will be live in-person and virtual.
- Full day meeting focusing on current issues in the field of anesthetic pharmacology.
- Approximately 125 attendees.

Supporter Levels

► Innovator - \$10,000 US

- Engagement/discussion with ISAP Leadership at a separate gathering (focus group type session)
- Opportunity to present sponsor content to the ISAP members (verbally or by video - pre and post annual meeting)
- Informational table at the meeting
- Logo placement on promotion materials and website
- Registrations to the ISAP annual meeting - 10
- Membership in ISAP - 10
- Use of ISAP membership list

► Partner - \$5,000 US

- Engagement/discussion with ISAP Leadership at annual meeting
- Opportunity to present sponsor content to the ISAP members (verbally or by video - pre and post annual meeting)
- Informational table at the meeting
- Logo placement on promotion materials and website
- Registrations to the ISAP annual meeting - 5
- Membership in ISAP - 5
- Use of ISAP membership list

► Entrepreneur - \$2,000 US

Companies with 100 employees or fewer.

- Opportunity to present sponsor content to the ISAP members (verbally or by video - pre and post annual meeting)
- Logo placement on promotion materials and website
- Informational table at the meeting
- Registrations to the ISAP annual meeting - 2
- Membership in ISAP - 2
- Use of ISAP membership list

2025 Board of Directors

President

Jerry Ingrande, MD, MS
University of California, San Diego

Vice President

Rik Carette, MD
AZORG hospitals Aalst, Belgium

Immediate Past President

Joseph Foss, MD
Cleveland Clinic

Director - 2023-2025

Howard Gutstein, MD, FASA
UConn Health, Dept of Anesthesiology

Director - 2023-2025

James H. Philip, MEE, MD
Brigham & Women's Hospital, Harvard Medical School, Dept. of Anesthesia

Director - 2024-2026

Klaus H. Hoerauf, MD, PhD
Medical University of Vienna, Austria

Director - 2024-2026

Talmage Egan, MD
University of Utah

A&A Section Editor

Markus Holmann, MD, PhD, DEAA
Amsterdam University Medical Center (AUMC)

A&A Section Editor

Ken Johnson, MD
University of Utah

Historian

Tom Krejcie, MD
Northwestern University

Executive Director

Jane Svinicki

34th Annual Meeting Schedule

0945–1730 Central Time Zone, USA

0945–1000	Welcome and announcements <i>Jerry Ingrande, MD, President</i>
1000–1200	Target Controlled Infusion Technology: An Update <i>Talmage Egan, MD, Moderator</i>
1000–1020	TCI as a Gain Switch: Conceptual and Historical Overview <i>Talmage D. Egan, MD, University of Utah, Salt Lake City, UT</i>
1020–1040	Lessons Learned from Decades of TCI Practice <i>C.F. Minto, MD, Anesthesiologist, Royal North Shore Hospital, Sydney, New South Wales, Australia</i>
1040–1100	Do the New “Uber” Models Make a Difference <i>Michel Struys, MD, PhD, FRCA (Hon), University of Groningen, University Medical Center Groningen, Netherlands</i>
1100–1120	From Target to Feedback: TCI in the Age of Closed-Loop Intelligent Autonomy <i>Kai Kuck, PhD, Professor Dept. of Anesthesiology and Director of Bioengineering, University of Utah, Salt Lake City, UT, USA</i>
1120–1200	Q&A
1200–1230	ISAP Board of Directors Business Meeting
1230–1400	Luncheon & Keynote Speaker & Lifetime Achievement Awardee Thomas Schnider, MD <i>Head of Department Institut für Anästhesiologie at Kantonsspital, St. Gallen, Switzerland (retired August 2023)</i>
1400–1445	Mohamed Naguib Lecture Guy Weinberg, MD, <i>Professor, Department of Anesthesiology, University of Illinois - College of Medicine, Chicago, Illinois</i>
1445–1615	Abstract Presentations
1615–1730	Board Meeting



LUNCHEON & KEYNOTE SPEAKER & LIFETIME ACHIEVEMENT AWARDEE

Thomas Schnider, MD

Head of Department Institut für Anästhesiologie at Kantonsspital, St. Gallen, Switzerland (retired August 2023)

Thomas Schnider is the former Head of Anesthesiology at Kantonsspital, St. Gallen, Switzerland. He received his MD degree from the University of Bern in Switzerland in 1984. Dr. Schnider worked as a Research Fellow at the Department of Anesthesiology, Stanford University, Stanford, California in clinical pharmacology. His main research interests are in pharmacokinetic/pharmacodynamic modeling and feedback control in anesthesia. He is the author or co-author of over 70 original publications, review articles case reports and and book chapters.

MOHAMED NAGUIB LECTURE

Guy Weinberg, MD

Professor, Department of Anesthesiology, University of Illinois - College of Medicine, Chicago, Illinois

Dr. Weinberg is best known for the discovery that infusing lipid emulsion (ILE) can attenuate or reverse local anesthetic systemic toxicity, LAST. This approach is now considered a standard of care for treating LAST. Dr. Weinberg initially trained at UCSF, receiving board certification in Internal Medicine and Medical Genetics before doing a research fellowship at the NIH. He then switched gears and careers to do a residency in Anesthesiology at UVA Charlottesville where he learned regional anesthesia working under Harold Carron, Cosmo DiFazio, and John Rowlingson. After moving to Chicago, where he worked at Michael Reese Hospital and the University of Illinois, a single peculiar clinical event led to studies of novel molecular targets of local anesthetics and eventually to the discovery that ILE can reduce related toxicity. His lab at the Jesse Brown VA focused on this phenomenon and its underlying mechanisms for more than 20 years. Dr. Weinberg chaired the ASRA working group on LAST for more than a decade and helped form the first advisories for treating LAST. He now co-hosts an annual workshop in Telluride, CO where leading scientists from around the world meet to discuss data on a set of genes, YAP and WWTR1 (TAZ), that contribute to many types of cancer.

